Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

ClinicalTrials.gov ID: NCT02669433

Public ClinicalTrials.gov record NCT02669433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Study identification

NCT ID
NCT02669433
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Axovant Sciences Ltd.
Industry
Enrollment
484 participants

Conditions and interventions

Interventions

  • RVT-101 35 mg Drug
  • RVT-101 70 mg Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2015
Primary completion
Nov 30, 2017
Completion
Nov 30, 2017
Last update posted
Apr 25, 2019

2016 – 2017

United States locations

U.S. sites
31
U.S. states
18
U.S. cities
29
Facility City State ZIP Site status
US138 Phoenix Arizona 85006
US108 Phoenix Arizona 85013
US139 Sun City Arizona 85351
US125 Tucson Arizona 85704
US119 Irvine California 92868
US134 Oxnard California 93030
US133 Rancho Mirage California 92270
US140 Sacramento California 95816
US141 Englewood Colorado 80113
US123 Washington D.C. District of Columbia 20007
US104 Boca Raton Florida 33431
US116 Boca Raton Florida 33486
US111 Jacksonville Florida 32224
US122 Orlando Florida 32806
US137 Palm Beach Gardens Florida 33410
US126 Tampa Florida 33609
US136 Atlanta Georgia 30331
US112 Chicago Illinois 60612
US118 Indianapolis Indiana 46202
US105 Lexington Kentucky 40536
US135 Newton Massachusetts 02459
US130 Quincy Massachusetts 02196
US102 Rochester Minnesota 55905
US109 New York New York 10032
US100 Chapel Hill North Carolina 27514
US110 Cleveland Ohio 44195
US106 Columbus Ohio 43210
US131 Portland Oregon 97210
US120 Willow Grove Pennsylvania 19090
US124 Dallas Texas 75390
US101 Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02669433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 25, 2019 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02669433 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →